HomeRenalGuard Solutions

RenalGuard Solutions

New Study Demonstrates Feasibility of Using RenalGuard-Guided Diuretic Therapy for Acute Heart Failure Patients

5/26/18: “We are thrilled to reveal late-breaking data that demonstrates a promising step towards a new therapy for patients suffering from Acute Decompensated Heart Failure,” says Jim Dillon, CEO of RenalGuard Solutions. “RenalGuard-Guided Diuretic Therapy has the potential to establish a new front-line standard of care for heart failure patients, allowing physicians to maximize fluid removal while protecting patients from the potential negative impact of excessive fluid loss.”